Home > Publications Database > How can we reduce psychological burden for patients of amyotrophic lateral sclerosis and their family caregivers? - Insights from the participatory multi-method study 'potentiALS'. > print

001     281635
005     20251103102758.0
024 7 _ |a 10.1186/s12883-025-04440-w
|2 doi
024 7 _ |a pmid:41057832
|2 pmid
037 _ _ |a DZNE-2025-01158
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Heyne, Svenja
|0 0000-0002-7980-484X
|b 0
245 _ _ |a How can we reduce psychological burden for patients of amyotrophic lateral sclerosis and their family caregivers? - Insights from the participatory multi-method study 'potentiALS'.
260 _ _ |a London
|c 2025
|b BioMed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1762161403_20023
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Amyotrophic lateral sclerosis (ALS) is a progressive, fatal motor neuron disease that severely impacts patients' physical and emotional well-being, while also imposing significant burdens on family caregivers. Despite the high psychosocial demands as part of the multidimensional burden, evidence for effective interventions remains limited. This study employed a participatory approach to assess the support needs of ALS patients and caregivers and to evaluate their preferences for psychosocial therapies to derive a therapeutic framework.In this observational multi-method study, ALS patients, their family caregivers, and healthcare professionals (HCPs) were actively involved throughout the research process. Quantitative Data were collected through structured questionnaires assessing quality of life (e.g., MQoL, SEIQoL-Q), depression and anxiety (ADI-12, HADS), and caregiver burden (BSFC-s). Feedback was obtained through structured group sessions that combined brief introductions, practical exercises, and subsequent evaluations of four therapy approaches - cognitive behavioral therapy (CBT), psychodynamic therapy (PT), acceptance and commitment therapy (ACT), and meaning-centered therapy (MCT).14 patients, 17 caregivers and nine HCPs participated in the study. Among patients, ACT was the most frequently selected (37.5%), followed by CBT (31.3%), MCT (18.8%), and PT (12.5%) with similar distribution in caregiver attendance. Across all therapy approaches, both patients and caregivers rated the beneficial aspects highly (mean scores of 4.18, and 4.12, respectively, on a scale from 1 to 5) and identified relatively few limitations (mean scores of 2.18 and 2.09, respectively, on a scale from 1 to 5). HCPs corroborated these findings, noting that while the therapies were effective in offering emotional support and facilitating open dialogue, challenges such as time constraints and adapting interventions for speech limitations remain. Notably, caregivers showed a strong preference for individualized therapy, while patients favored a mix of individual and group formats.Our study highlights the distinct yet interconnected psychosocial needs of ALS patients and their caregivers. Tailored interventions should blend emotional support, open dialogue, and a structured therapeutic framework, while also emphasizing the need for adaptable delivery models in clinical practice. These findings support the development of scalable, patient-centered psychosocial support approaches as part of the multidimensional care in ALS.The trial is registered at ClinicalTrials.gov (number: NCT06441448, registration date: May 28, 2024).
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Amyotrophic lateral sclerosis
|2 Other
650 _ 7 |a Family caregivers
|2 Other
650 _ 7 |a Participatory approach
|2 Other
650 _ 7 |a Psychotherapy
|2 Other
650 _ 7 |a Supportive care
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Amyotrophic Lateral Sclerosis: psychology
|2 MeSH
650 _ 2 |a Amyotrophic Lateral Sclerosis: therapy
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Caregivers: psychology
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Quality of Life: psychology
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Cost of Illness
|2 MeSH
650 _ 2 |a Surveys and Questionnaires
|2 MeSH
650 _ 2 |a Cognitive Behavioral Therapy: methods
|2 MeSH
700 1 _ |a Kuzmanova, Adelina
|b 1
700 1 _ |a Esser, Peter
|b 2
700 1 _ |a Linse, Katharina
|0 P:(DE-2719)2812121
|b 3
|u dzne
700 1 _ |a Günther, René
|0 P:(DE-2719)2811849
|b 4
|u dzne
700 1 _ |a Mehnert-Theuerkauf, Anja
|b 5
700 1 _ |a Metelmann, Moritz
|b 6
773 _ _ |a 10.1186/s12883-025-04440-w
|g Vol. 25, no. 1, p. 414
|0 PERI:(DE-600)2041347-6
|n 1
|p 414
|t BMC neurology
|v 25
|y 2025
|x 1471-2377
856 4 _ |u https://pub.dzne.de/record/281635/files/DZNE-2025-01158%20SUP1.docx
856 4 _ |u https://pub.dzne.de/record/281635/files/DZNE-2025-01158%20SUP2.docx
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/281635/files/DZNE-2025-01158.pdf
856 4 _ |u https://pub.dzne.de/record/281635/files/DZNE-2025-01158%20SUP1.doc
856 4 _ |u https://pub.dzne.de/record/281635/files/DZNE-2025-01158%20SUP1.odt
856 4 _ |u https://pub.dzne.de/record/281635/files/DZNE-2025-01158%20SUP1.pdf
856 4 _ |u https://pub.dzne.de/record/281635/files/DZNE-2025-01158%20SUP2.doc
856 4 _ |u https://pub.dzne.de/record/281635/files/DZNE-2025-01158%20SUP2.odt
856 4 _ |u https://pub.dzne.de/record/281635/files/DZNE-2025-01158%20SUP2.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/281635/files/DZNE-2025-01158.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:281635
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 3
|6 P:(DE-2719)2812121
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2811849
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-27
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-27
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BMC NEUROL : 2022
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-04-10T15:34:49Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-04-10T15:34:49Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-27
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-27
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-27
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-27
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-27
920 1 _ |0 I:(DE-2719)1710012
|k AG Falkenburger
|l Translational Parkinson Research
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1710012
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21